Should You Buy Doximity Inc (DOCS) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
38.630
1 Day change
-0.26%
52 Week Range
85.210
Analysis Updated At
2026/01/28
DOCS is NOT a good buy right now for a beginner, long-term investor who is impatient and doesn’t want to wait for a cleaner entry. The stock is in a clear short-term downtrend (bearish moving averages and worsening MACD), and near-term headlines/policy uncertainty plus an upcoming earnings event (2026-02-05) raise the odds of additional downside before the trend stabilizes. It becomes more attractive after it either (1) holds and rebounds convincingly off the 38.02–38.89 support area, or (2) reclaims the ~40.30 pivot and starts building higher highs.
Technical Analysis
Trend is bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating sustained downside momentum. MACD histogram is negative (-0.086) and expanding to the downside, which typically signals the downtrend is still strengthening rather than bottoming. RSI(6) is ~22.97, which is effectively oversold (even though the feed labels it “neutral”), so a short bounce is possible—but oversold readings can persist in downtrends. Key levels: immediate support S1=38.889 then S2=38.021; resistance/pivot at ~40.295, then R1=41.701. With post-market around 39.03, price is sitting just above support, meaning risk of a support break is meaningful.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Options positioning is mildly bullish/neutral (put-call ratios below 1), suggesting slightly more call interest than puts—not extreme. Volume is elevated (today’s volume ~123% of 30-day average), implying increased attention/positioning. Implied volatility (30D IV ~44.72) is below historical volatility (~56.62) and IV rank is low (~9.43), which suggests options are not pricing unusually large moves versus the stock’s history; sentiment isn’t panicky, but it also doesn’t signal a strong “capitulation bottom.” Overall: options lean mildly constructive, but not strong enough to override the bearish technical trend.
Technical Summary
Sell
9
Buy
5
Positive Catalysts
Multiple recent analyst upgrades/positive initiations (Truist to Buy; RBC initiated Outperform; Wells Fargo upgraded to Overweight; Goldman upgraded to Neutral) can support sentiment and flows.
Upcoming earnings (QDEC 2025 report on 2026-02-05 after hours) could reset expectations if results/forward commentary are better than feared.
Fundamentals remain strong in the latest reported quarter (high margins, solid YoY growth) and product expansion narrative (e.g., OpenEvidence tools) is viewed positively by some analysts/partners.
Neutral/Negative Catalysts
Policy/news overhang: Medicare telehealth reimbursement changes highlighted in recent news may weigh on the broader telehealth/digital health complex and sentiment around DOCS.
Recent news flow emphasizes slowing revenue growth and investor pessimism; DOCS recently sold off alongside peers.
Technical trend is still declining (bearish MA stack + worsening MACD), increasing the risk that supports at 38.89 and 38.02 get tested or broken.
Near-term event risk: earnings on 2026-02-05 can create volatility and downside gaps if guidance/disclosure disappoints.
Financial Performance
Latest quarter provided: 2026/Q2. Revenue rose to $168.525M (+23.16% YoY), Net Income increased to $62.059M (+40.55% YoY), and EPS grew to $0.31 (+40.91% YoY). Gross margin was exceptionally high at ~90.25% (slightly up YoY). This shows strong profitability and solid growth trends in the reported quarter, even as market narrative points to slowing growth versus prior expectations.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent analyst trend: ratings have improved (several upgrades and an Outperform initiation), but many price targets were cut versus prior levels—signaling that Wall Street is becoming more constructive on quality/positioning while also tempering growth/visibility expectations. Notable changes: Wells Fargo upgraded to Overweight with PT $55 (cut from $65); Goldman upgraded to Neutral with PT $49 (cut from $62); Truist upgraded to Buy with PT $62; RBC initiated Outperform with PT $59; KeyBanc stayed Overweight but cut PT to $60 (from $75).
Wall Street pros: differentiated platform with a large physician network (moat), strong margins, and product expansion potential (OpenEvidence) with some indications of good ROI for pharma spend.
Wall Street cons: slower/less visible revenue growth, competitive concerns, and healthcare spending/policy uncertainty.
Influential/politician trading: no recent Congress trading data available; hedge funds and insiders are both described as Neutral with no significant recent trends.
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 62.75 USD with a low forecast of 50 USD and a high forecast of 82 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 62.75 USD with a low forecast of 50 USD and a high forecast of 82 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
4 Hold
1 Sell
Moderate Buy
Current: 38.730
Low
50
Averages
62.75
High
82
Current: 38.730
Low
50
Averages
62.75
High
82
Wells Fargo
Stan Berenshteyn
Equal Weight -> Overweight
upgrade
$65 -> $55
AI Analysis
2026-01-20
Reason
Wells Fargo
Stan Berenshteyn
Price Target
$65 -> $55
AI Analysis
2026-01-20
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo analyst Stan Berenshteyn upgraded Doximity to Overweight from Equal Weight with a price target of $55, down from $65. The firm views investor concerns as overdone after its survey indicated Doximity has "sufficient differentiation." While low visibility and completive concerns have been pressuring the shares, Wells' survey supports "platform staying power" for Doximity, the analyst tells investors in a research note. The firm believes the shares can move higher without a pickup in revenue growth.
Goldman Sachs
David Roman
Sell -> Neutral
upgrade
$62 -> $49
2026-01-09
Reason
Goldman Sachs
David Roman
Price Target
$62 -> $49
2026-01-09
upgrade
Sell -> Neutral
Reason
Goldman Sachs analyst David Roman upgraded Doximity to Neutral from Sell with a price target of $49, down from $62. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note. The firm sees valuation re-based and consensus numbers more accurately capturing the Doximity's forward outlook.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DOCS
